Kathy A. Nelson, MBA, RDH

• Develop and execute regional and national business plans.
• Onboard an additional four authorized treatment centers for an investigational cell therapy (allogenic virus-specific T cells) in three months.
• Medical expert engagement.
• Identify key stakeholders in the fields of bone marrow transplant (BMT), lymphoma, solid organ transplantation (SOT), and specialists managing post-transplant lymphoproliferative disease (PTLD).
• Design strategies to align processes with cellular therapy labs and transplant centers.
• Numerous cross-functional workstreams: Marketing, Training, and Data Analytics.
• Identify potential market access barriers to ensure the investigational launch product is well positioned for P&T reviews.
• Facilitate and ensure collective, cross-functional communication and collaboration with internal teams, including Value & Access, Medical Affairs, Legal, Quality, Technical Operations, Marketing, and Patient Affairs.

• Develop a territory in the South-Central Region for an oncology start-up business unit in cellular therapy. Territory includes IDN's, hospitals, academic institutions, bone marrow transplant centers, solid organ transplantation, and cellular and gene therapy labs.
• Develop and execute territory business plans, which include account-specific strategies and tactics for physician advocacy, and timely patient access.
• Onboard 13 authorized treatment centers in four months.
• Facilitate cross-functional relationships with internal and institutional stakeholders, including the C-suite, procurement, revenue cycle, and P&T Committee.
• Navigate activities associated with onboarding institutions for cellular therapy (Non-Disclosure Agreements, Data Processing Agreements, IT Risk Assessments, Trade Agreements, portal education and training, Cellular Therapy Standard Operating Procedures, and product handling).
• Drive appropriate advocacy for Pierre Fabre products through scientific exchange.
• Partner with the U.S. Market Access Team to support the execution of the U.S. Access strategy and tactics to ensure patient access.

SMU Cox School of Business is an immersive curriculum with rigorous academics, experiential learning, and includes a global perspective.

Development of skills to navigate complex problems and succinctly communicate data insights with a diverse, collaborative cohort of colleagues.

• Manage Retina Accounts and affiliated surgical centers throughout North Texas.
• Launch of faricimab (VABYSMO): the first and only bi-specific antibody for intravitreal use.
• Launch of a port delivery system (SUSVIMO) ocular implant for intravitreal use: the first and only drug-device combination FDA-approved for nAMD (wet, age-related macular degeneration).
• Increased market share by over 114% by executing a strategy that implemented recapturing growth for LUCENTIS.
• Marketing workstreams: organizational alignment of competitive implications, designing tactics to outmaneuver potential challenges, and building an insurmountable position based on competitive intelligence.
• Reimbursement landscape insights, which include coding, billing, EMR, formulary decision process, buy-and-bill purchasing process, and patient support services.

• Develop a territory in the state of Texas for an oncology start-up company in the hematology and oncology landscape.
• Launch Acceleron's first commercial sales field team and first FDA-approved commercial product, luspatercept (Reblozyl).
• Execute strategic business plans for swift growth and adoption, with rapid, successful penetration of top-tier accounts.
• Develop, collaborate, and execute account action plans with cross-functional partners, both internally and externally, including MSLs, specialty pharmacy liaisons, and market access.
• Exceeding 2020 goals, despite pandemic constraints.
• Awarded for Launch Performance and Territory Growth.

• Launch multiple indications for venetoclax (VENCLEXTA).
• Sales & Marketing Coordination Council (SMCC) for 2019-2020: strategic development of resources with the Marketing Team for the Commercial Field, utilizing CRM initiatives.
• AML Strike Force Team, providing field business insights, analytics, and competitive intelligence throughout the launch.
• Market access communication of pharmacy benefit policies for an oral oncolytic in buy-and-bill, and specialty pharmacy.
• Reimbursement landscape insights, including coding, billing, EMR, formulary, and pathway decision processes, buy-and-bill purchasing processes, and patient support services.
• Oncology

• Launch multiple indications for blinatumomab (BLINCYTO); the first bi-specific T-cell engager therapy (BiTE) for acute lymphocytic leukemia.
• Strategically planned and implemented inpatient-to-outpatient therapy coordination, with the 28-day continuous infusion requirement for therapy.
• Developed and led inpatient and outpatient nurse and pharmacy training.
• Awards: Chairman's Circle (2016), MVP Leadership (2016), Team Excellence (2014 and 2016), and Ultimate Race Contest (2013 and 2016).
• Leadership workstreams: Shark Tank Team (2016), Council of Sales Advisors (2016-2017), and Amgen Women in Network (2015-2017).